Voyager Therapeutics (VYGR) Receivables (2022 - 2026)

Voyager Therapeutics has disclosed Receivables across 5 years of filings, most recently posting $1.6 million for Q1 2026.

• Receivables for Q1 2026 came in at $1.6 million, down 22.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 22.04% YoY), and the FY2025 annual result was $1.9 million, down 12.29% from the prior year.
• Receivables came in at $1.6 million for Q1 2026 at Voyager Therapeutics, down from $1.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $83.5 million in Q4 2023 to a low of $1.6 million in Q1 2026.
• The 5-year median for Receivables is $3.4 million (2024), against an average of $13.3 million.
• Across the five-year window, Receivables slumped 97.39% in 2024 and declined 12.29% in 2025, its largest moves.
• Voyager Therapeutics' Receivables stood at $10.2 million in 2022, then soared by 716.54% to $83.5 million in 2023, then plunged by 97.39% to $2.2 million in 2024, then slipped by 12.29% to $1.9 million in 2025, then decreased by 13.96% to $1.6 million in 2026.
• The last three Receivables figures came in at $1.6 million (Q1 2026), $1.9 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.